keyword
https://read.qxmd.com/read/38352404/dynamic-regulation-of-cea-gene-expression-during-acute-and-protracted-abstinence-from-chronic-binge-drinking-of-male-and-female-c57bl-6j-mice
#21
Hernán G Méndez, Sofia Neira, Meghan E Flanigan, Harold L Haun, Kristen M Boyt, Todd E Thiele, Thomas L Kash
Binge alcohol consumption is a major risk factor for developing Alcohol Use Disorder (AUD) and is associated with alcohol-related problems like accidental injury, acute alcohol poisoning, and black-outs. While there are numerous brain regions that have been shown to play a role in this AUD in humans and animal models, the central nucleus of the amygdala (CeA) has emerged as a critically important locus mediating binge alcohol consumption. In this study, we sought to understand how relative gene expression of key signaling molecules in the CeA changes during different periods of abstinence following bouts of binge drinking...
February 4, 2024: bioRxiv
https://read.qxmd.com/read/38338760/neurobiology-of-stress-induced-nicotine-relapse
#22
REVIEW
Xinyu Wang, Yun Chen, Jing Dong, Jing Ge, Xiaoliu Liu, Jianfeng Liu
Tobacco smoking is the leading cause of preventable death and disease. Although there are some FAD-approved medicines for controlling smoking, the relapse rate remains very high. Among the factors that could induce nicotine relapse, stress might be the most important one. In the last decades, preclinical studies have generated many new findings that lead to a better understanding of stress-induced relapse of nicotine-seeking. Several molecules such as α3β4 nicotinic acetylcholine receptor, α2-adrenergic receptors, cannabinoid receptor 1, trace amine-associated receptor 1, and neuropeptide systems (corticotropin-releasing factor and its receptors, dynorphine and kappa opioid receptor) have been linked to stress-induced nicotine relapse...
January 25, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38337707/a-combination-of-a-dopamine-receptor-2-agonist-and-a-kappa-opioid-receptor-antagonist-synergistically-reduces-weight-in-diet-induced-obese-rodents
#23
JOURNAL ARTICLE
Beatriz Cicuéndez, Javier Pérez-García, Cintia Folgueira
As the global obesity rate increases, so does the urgency to find effective anti-obesity drugs. In the search for therapeutic targets, central nervous system (CNS) mechanisms engaged in the regulation of energy expenditure and food intake, such as the opioid and dopamine systems, are crucial. In this study, we examined the effect on body weight of two drugs: bromocriptine (BC), a D2R receptor agonist, and PF-04455242, a selective κ opioid receptor (KOR) antagonist. Using diet-induced obese (DIO) rats, we aimed to ascertain whether the administration of BC and PF-04455242, independently or in combination, could enhance body weight loss...
January 31, 2024: Nutrients
https://read.qxmd.com/read/38294264/-diagnosis-and-management-of-pruritus-associated-with-chronic-kidney-disease-in-hemodialyzed-patients
#24
JOURNAL ARTICLE
Antoine Lanot, Laurent Misery, Guy Rostoker, Angelo Testa, Philippe Chauveau, Maxime Touzot, Nans Florens, Pierre Bataille
Chronic kidney disease-associated pruritus (CKD-aP) is a disabling symptom which is frequent and often underestimated. Pa-MRC has a negative impact on quality of life, and is frequently accompanied by sleep disorders and depression. The approval of difelikefalin – a kappa opioid receptor agonist – in this indication requires updated recommendations. As a first step, secondary causes of pruritus without skin lesions must be ruled out, and general measures taken (emollients, psychological support, optimization of dialysis, normalization of serum calcium, phosphate and PTH in the range proposed by the KGIDO guidelines, treatment of iron deficiency)...
January 31, 2024: Néphrologie & Thérapeutique
https://read.qxmd.com/read/38265210/identification-and-in-vivo-evaluation-of-myelination-agent-pipe-3297-a-selective-kappa-opioid-receptor-agonist-devoid-of-%C3%AE-arrestin-2-recruitment-efficacy
#25
JOURNAL ARTICLE
Thomas O Schrader, Kym I Lorrain, Didier Bagnol, Geraldine C Edu, Alexander Broadhead, Christopher Baccei, Michael M Poon, Karin J Stebbins, Yifeng Xiong, Ariana O Lorenzana, Jonah R Chan, Ari J Green, Daniel S Lorrain, Austin Chen
Structure-activity relationship studies led to the discovery of PIPE-3297, a fully efficacious and selective kappa opioid receptor (KOR) agonist. PIPE-3297, a potent activator of G-protein signaling (GTPγS EC50 = 1.1 nM, 91% E max ), did not elicit a β-arrestin-2 recruitment functional response ( E max < 10%). Receptor occupancy experiments performed with the novel KOR radiotracer [3 H]-PIPE-3113 revealed that subcutaneous (s.c.) administration of PIPE-3297 at 30 mg/kg in mice achieved 90% occupancy of the KOR in the CNS 1 h post dose...
January 24, 2024: ACS Chemical Neuroscience
https://read.qxmd.com/read/38256863/novel-opioids-in-the-setting-of-acute-postoperative-pain-a-narrative-review
#26
REVIEW
Ashley Wang, Jasper Murphy, Lana Shteynman, Neil Daksla, Abhishek Gupta, Sergio Bergese
Although traditional opioids such as morphine and oxycodone are commonly used in the management of acute postoperative pain, novel opioids may play a role as alternatives that provide potent pain relief while minimizing adverse effects. In this review, we discuss the mechanisms of action, findings from preclinical studies and clinical trials, and potential advantages of several novel opioids. The more established include oliceridine (biased ligand activity to activate analgesia and downregulate opioid-related adverse events), tapentadol (mu-opioid agonist and norepinephrine reuptake inhibitor), and cebranopadol (mu-opioid agonist with nociceptin opioid peptide activity)-all of which have demonstrated success in the clinical setting when compared to traditional opioids...
December 25, 2023: Pharmaceuticals
https://read.qxmd.com/read/38253309/nalbuphine-6-glucuronide-is-a-potent-analgesic-with-superior-safety-profiles-by-altering-binding-affinity-and-selectivity-for-mu-kappa-opioid-receptors
#27
JOURNAL ARTICLE
Yen-Lun Chen, Yen-Hsun Lai, Eagle Yi-Kung Huang, Hong-Jaan Wang, Hao-Yuan Hung
Although nalbuphine, a semi-synthetic analgesic compound, is less potent than morphine in terms of alleviating severe pain, our recent findings have revealed that nalbuphine-6-glucuronide (N6G), one of the glucuronide metabolites of nalbuphine, promotes a significantly more robust analgesic effect than its parent drug. Nevertheless, despite these promising observations, the precise mechanisms underlying the analgesic effects of nalbuphine glucuronides have yet to be determined. In this study, we aim to elucidate the mechanisms associated with the analgesic effects of nalbuphine glucuronides...
January 20, 2024: Life Sciences
https://read.qxmd.com/read/38234775/molecular-identification-of-wide-field-amacrine-cells-in-mouse-retina-that-encode-stimulus-orientation
#28
Silvia J Park, Wanyu Lei, John Pisano, Andrea Orpia, Jacqueline Minehart, Joseph Pottackal, Christin Hanke-Gogokhia, Thomas E Zapadka, Cheryl Clarkson-Paredes, Anastas Popratiloff, Sarah E Ross, Joshua H Singer, Jonathan B Demb
Visual information processing is sculpted by a diverse group of inhibitory interneurons in the retina called amacrine cells. Yet, for most of the >60 amacrine cell types, molecular identities and specialized functional attributes remain elusive. Here, we developed an intersectional genetic strategy to target a group of wide-field amacrine cells (WACs) in mouse retina that co-express the transcription factor Bhlhe22 and the Kappa Opioid Receptor (KOR; B/K WACs). B/K WACs feature straight, unbranched dendrites spanning over 0...
December 29, 2023: bioRxiv
https://read.qxmd.com/read/38187718/kappa-opioid-receptors-in-mesolimbic-terminals-mediate-escalation-of-cocaine-consumption
#29
L Gordon-Fennell, R D Farero, L M Burgeno, N L Murray, A D Abraham, M E Soden, G D Stuber, C Chavkin, L S Zweifel, P E M Phillips
Increases in drug consumption over time, also known as escalation, is a key behavioral component of substance use disorder (SUD) that is related to potential harm to users, such as overdose. Studying escalation also allows researchers to investigate the transition from casual drug use to more SUD-like drug use. Understanding the neurobiological systems that drive this transition will inform therapeutic treatments in the aim to prevent increases in drug use and the development of SUD. The kappa opioid receptor (KOR) system is typically known for its role in negative affect, which is commonly found in SUD as well...
December 23, 2023: bioRxiv
https://read.qxmd.com/read/38183534/the-antidepressant-effect-of-magnolol-on-depression-like-behavior-of-cort-treated-mice
#30
JOURNAL ARTICLE
Chi Xu, Jiayu Ye, Yanting Sun, Xiujian Sun, Jing-Gen Liu
Although the antidepressant-like effect of magnolol has been revealed in previous reports, the mechanism remains unclear. In this study, the antidepressant-like effect of magnolol on corticosterone-induced (CORT-induced) mice was investigated in vivo. After 21 days of CORT induction, the mice showed marked depressive-like behaviors, with a decrease in sucrose preference score and an increase in immobility time in the tail suspension test (TST) and forced swimming test (FST). Pretreatment with either magnolol (50 mg/kg, i...
January 6, 2024: Journal of Molecular Neuroscience: MN
https://read.qxmd.com/read/38182431/co-expressed-delta-mu-and-kappa-opioid-receptors-modulate-voltage-gated-ca-2-channels-in-gastric-projecting-vagal-afferent-neurons
#31
JOURNAL ARTICLE
Hannah J Goudsward, Victor Ruiz-Velasco, Salvatore L Stella, Lisa B Willing, Gregory M Holmes
Opioid analgesics are frequently associated with gastrointestinal (GI) side effects including constipation, nausea, dysphagia, and reduced gastric motility. Though it has been shown that stimulation of opioid receptors expressed in enteric motor neurons contributes to opioid-induced constipation, it remains unclear whether activation of opioid receptors in gastric-projecting nodose ganglia neurons contributes to the reduction in gastric motility and emptying associated with opioid use. In the present study, whole-cell patch-clamp recordings were performed to determine the mechanism underlying opioid receptor-mediated modulation of Ca2+ currents in acutely isolated gastric vagal afferent neurons...
January 5, 2024: Molecular Pharmacology
https://read.qxmd.com/read/38151714/gpcr-g-protein-selectivity-revealed-by-structural-pharmacology
#32
JOURNAL ARTICLE
Sarah M Bernhard, Jianming Han, Tao Che
Receptor-G protein promiscuity is frequently observed in class A G protein-coupled receptors (GPCRs). In particular, GPCRs can couple with G proteins from different families (Gαs, Gαq/11, Gαi/o, and Gα12/13) or the same family subtypes. The molecular basis underlying the selectivity/promiscuity is not fully revealed. We recently reported the structures of kappa opioid receptor (KOR) in complex with the Gi/o family subtypes [Gαi1, GαoA, Gαz, and Gustducin (Gαg)] determined by cryo-electron microscopy (cryo-EM)...
December 27, 2023: FEBS Journal
https://read.qxmd.com/read/38141084/safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-a-novel-kappa-opioid-receptor-agonist-zykr1-a-randomized-double-blind-placebo-control-phase-1-study-in-healthy-adult-human-participants
#33
JOURNAL ARTICLE
Kevinkumar A Kansagra, Taufik Momin, Hardik B Patel, Chintan Shah, Gordhan Parmar, Ashok Ghoghari, Harilal V Patel, Deven V Parmar
To perform first-in-human single-dose escalation trial of ZYKR1, which is a potent, selective, and peripherally-restricted kappa opioid receptor agonist, is the purpose of this study. This randomized, double-blind, placebo-controlled single ascending dose study conducted at Zydus Research Centre, Ahmedabad, India included healthy male participants aged 18-55 years and weighing > 50 kg. The primary objective was to evaluate the safety and tolerability of ZYKR1. The secondary objective was to evaluate the pharmacokinetics and pharmacodynamics (PD) of ZYKR1...
December 23, 2023: Naunyn-Schmiedeberg's Archives of Pharmacology
https://read.qxmd.com/read/38114634/correction-dynorphin-kappa-opioid-receptor-regulation-of-excitation-inhibition-balance-toggles-afferent-control-of-prefrontal-cortical-circuits-in-a-pathway-specific-manner
#34
Hector E Yarur, Sanne M Casello, Valerie S Tsai, Juan Enriquez-Traba, Rufina Kore, Huikun Wang, Miguel Arenivar, Hugo A Tejeda
No abstract text is available yet for this article.
December 19, 2023: Molecular Psychiatry
https://read.qxmd.com/read/38099236/kappa-opioid-agonists-in-the-treatment-of-itch-just-scratching-the-surface
#35
JOURNAL ARTICLE
Tyler C Beck, Elena M Wilson, Erik Wilkes, Lara Wine Lee, Russell Norris, Manuel Valdebran
Chronic pruritus is a debilitating condition affecting 23-44 million Americans. Recently, kappa opioid agonists (KOAs) have emerged as a novel class of potent antipruritic agents. In 2021, the Food and Drug Administration approved difelikefalin (Korsuva) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. Difelikefalin is a potent, peripherally restricted KOA that is intravenously available. Although promising, difelikefalin is currently available as an intravenous composition only, limiting the scope of use...
2023: Itch
https://read.qxmd.com/read/38090669/enhanced-and-complementary-benefits-of-a-nalfurafine-and%C3%A2-fingolimod-combination-to-treat-immune-driven-demyelination
#36
JOURNAL ARTICLE
Katharina Robichon, Rabia Bibi, Mackenzie Kiernan, Lisa Denny, Thomas E Prisinzano, Bronwyn M Kivell, Anne Camille La Flamme
OBJECTIVES: Multiple sclerosis (MS) is a neurodegenerative disease characterised by inflammation and damage to myelin sheaths. While all current disease-modifying treatments (DMTs) are very effective at reducing relapses, they do not slow the progression of the disease, and there is little evidence that these treatments are able to repair or remyelinate damaged axons. Recent evidence suggests that activating kappa opioid receptors (KORs) has a beneficial effect on the progression of MS, and this study investigates the effects of KOR agonists treatment in combination with two current DMTs...
2023: Clinical & Translational Immunology
https://read.qxmd.com/read/38084074/preclinical-models-of-attention-deficit-hyperactivity-disorder-neurobiology-drug-discovery-and-beyond
#37
JOURNAL ARTICLE
Deirdre M McCarthy, Thomas J Spencer, Pradeep G Bhide
OBJECTIVE: We offer an overview of ADHD research using mouse models of nicotine exposure. METHOD: Nicotine exposure of C57BL/6 or Swiss Webster mice occurred during prenatal period only or during the prenatal and the pre-weaning periods. Behavioral, neuroanatomical and neurotransmitter assays were used to investigate neurobiological mechanisms of ADHD and discover candidate ADHD medications. RESULTS: Our studies show that norbinaltorphimine, a selective kappa opioid receptor antagonist is a candidate novel non-stimulant ADHD treatment and that a combination of methylphenidate and naltrexone has abuse deterrent potential with therapeutic benefits for ADHD...
December 12, 2023: Journal of Attention Disorders
https://read.qxmd.com/read/38052802/design-and-structural-validation-of-peptide-drug-conjugate-ligands-of-the-kappa-opioid-receptor
#38
JOURNAL ARTICLE
Edin Muratspahić, Kristine Deibler, Jianming Han, Nataša Tomašević, Kirtikumar B Jadhav, Aina-Leonor Olivé-Marti, Nadine Hochrainer, Roland Hellinger, Johannes Koehbach, Jonathan F Fay, Mohammad Homaidur Rahman, Lamees Hegazy, Timothy W Craven, Balazs R Varga, Gaurav Bhardwaj, Kevin Appourchaux, Susruta Majumdar, Markus Muttenthaler, Parisa Hosseinzadeh, David J Craik, Mariana Spetea, Tao Che, David Baker, Christian W Gruber
Despite the increasing number of GPCR structures and recent advances in peptide design, the development of efficient technologies allowing rational design of high-affinity peptide ligands for single GPCRs remains an unmet challenge. Here, we develop a computational approach for designing conjugates of lariat-shaped macrocyclized peptides and a small molecule opioid ligand. We demonstrate its feasibility by discovering chemical scaffolds for the kappa-opioid receptor (KOR) with desired pharmacological activities...
December 6, 2023: Nature Communications
https://read.qxmd.com/read/38044924/efficacy-of-intravenous-nalbuphine-for-managing-post-anaesthesia-shivering-a-systematic-review-and-meta-analysis-of-randomised-controlled-trials-with-trial-sequential-analysis
#39
JOURNAL ARTICLE
Abhijit Nair, Ujjwalraj Dudhedia, Manamohan Rangaiah, Suhrud Panchawagh
BACKGROUND AND AIMS: Post-anaesthesia shivering is distressing and is observed after spinal and general anaesthesia. Nalbuphine, a partial mu-opioid receptor antagonist with kappa-opioid receptor agonist properties, has been successfully used to manage post-anaesthesia shivering. METHODS: After registering the review with the International Prospective Register of Systematic Reviews (PROSPERO), we searched PubMed/Medline, Scopus, Ovid, Cochrane Library and clinicaltrials...
October 2023: Indian Journal of Anaesthesia
https://read.qxmd.com/read/38036264/sex-differences-in-descending-control-of-nociception-dcn-responses-after-chronic-orofacial-pain-induction-in-rats-and-the-contribution-of-kappa-opioid-receptors
#40
JOURNAL ARTICLE
Fernanda Fiatcoski, Carlos Henrique Alves Jesus, Joelle de Melo Turnes, Juliana Geremias Chichorro, Caroline Machado Kopruszinski
Descending control of nociception (DCN), a measure of efficiency of descending pain inhibition, can be assessed in animals by the combined application of test and conditioning noxious stimuli. Evidence from pre-clinical and clinical studies indicates that this mechanism of pain control may differ between sexes and might be impaired in many chronic pain states. However, little is known about sex differences in DCN efficiency in models of acute and chronic orofacial pain. Herein, we first evaluated DCN responses in male and female rats by the applying formalin into the upper lip or capsaicin into the forepaw as the conditioning stimulus, followed by mechanical stimulation (Randall-Selitto) of the hind paw as the test stimulus...
November 29, 2023: Behavioural Brain Research
keyword
keyword
57781
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.